Thill, Marc http://orcid.org/0000-0002-8800-8044
Wimberger, Pauline http://orcid.org/0000-0002-7380-577X
Grafe, Andrea http://orcid.org/0000-0003-2404-9688
Klare, Peter
Luedtke-Heckenkamp, Kerstin
Reichert, Dietmar
Zaiss, Matthias
Ziegler-Löhr, Katja http://orcid.org/0000-0003-1588-1819
Eckl, Tanja
Schneeweiss, Andreas http://orcid.org/0000-0002-2429-4512
Funding for this research was provided by:
F. Hoffmann-La Roche
Article History
Received: 10 February 2022
Accepted: 3 August 2022
First Online: 12 September 2022
Declarations
:
: Prof. M. Thill reports personal fees from Amgen, AstraZeneca, Celgene (inc. non-financial), Clearcut, Clovis, Daiichi Sankyo, Gilead Science, Eisai, Exact Science (including non-financial and grants (trialfunding)), Lilly, MSD, Hexal, Neodynamics, Novartis, Pfizer, pfm medical (including non-financial, writing assistance), Roche (including non-financial writing assistance), Pierre Fabre, Tesaro, Clovis, Seagen, Servier, Clearcut, Organon, Viatris, Becton Dickinson, Symex, Vifor and a grant from Endomag, Prof. P Wimberger reports honoraria and contracted research from Amgen, AstraZeneca, MSD, Novartis, Pfizer, Lilly, Roche, Teva, Eisai, Clovis and GSK, Prof. A. Schneeweiss reports research grants from Celgene, Roche and Abbvie, personal fees from Roche (travel expenses, expert testimony, honoraria, medical writing), personal fees from AstraZeneca personal fees (travel expenses, honoraria and expert testimony), personal fees from Celgene (travel expenses and expert testimony), personal fees from Pfizer (travel expenses and expert testimony), honoraria from Novartis, MSD, Tesaro, Lilly and Seagen, Dr. T. Eckl holds stocks and is an employee of Roche Pharma Germany, Dr. K. Luedtke-Heckenkamp receives consulting fees from AstraZeneca, Eisai, Novartis, Pfizer, Roche and Seagen, Dr. M. Zaiss receives consulting fees from Roche, Abbvie, AstraZeneca, Lilly, Janssen, Celgene, Pfizer, Novartis, Vifor, Gilead, fees from non-CME-services from Pfizer, Vifor, AstraZeneca and contracted research from Roche, Novartis and AstraZeneca; Dr. K. Ziegler-Löhr receives consulting fees from Roche, Novartis, Tesaro, from contracted research with Roche, Novartis, Tesaro and has ownership interests in Daiichi Sankyo. Dr. A. Grafe, Dr. P. Klare, and Dr. D. Reichert reported to not have received personal fees.